206 related articles for article (PubMed ID: 35018469)
1. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
Kotch C; Avery R; Getz KD; Bouffet E; de Blank P; Listernick R; Gutmann DH; Bornhorst M; Campen C; Liu GT; Aplenc R; Li Y; Fisher MJ
Neuro Oncol; 2022 Aug; 24(8):1377-1386. PubMed ID: 35018469
[TBL] [Abstract][Full Text] [Related]
2. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
3. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
Dalla Via P; Opocher E; Pinello ML; Calderone M; Viscardi E; Clementi M; Battistella PA; Laverda AM; Da Dalt L; Perilongo G
Neuro Oncol; 2007 Oct; 9(4):430-7. PubMed ID: 17704361
[TBL] [Abstract][Full Text] [Related]
4. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat.
Azizi AA; Walker DA; Liu JF; Sehested A; Jaspan T; Pemp B; Simmons I; Ferner R; Grill J; Hargrave D; Driever PH; Evans DG; Opocher E;
Neuro Oncol; 2021 Jan; 23(1):100-111. PubMed ID: 32628746
[TBL] [Abstract][Full Text] [Related]
5. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
6. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
Falzon K; Drimtzias E; Picton S; Simmons I
Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
8. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
Florent C; Beylerian M; Mairot K; Dambricourt L; André N; David T; Girard N; Audic F; Denis D
J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579
[TBL] [Abstract][Full Text] [Related]
10. The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis.
Kotch C; Si SJ; Desai K; Caminada P; Lo Russo FM; Li Y; Liu GT; Avery RA; Fisher MJ
J Neurooncol; 2023 Sep; 164(3):741-747. PubMed ID: 37803102
[TBL] [Abstract][Full Text] [Related]
11. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.
King A; Listernick R; Charrow J; Piersall L; Gutmann DH
Am J Med Genet A; 2003 Oct; 122A(2):95-9. PubMed ID: 12955759
[TBL] [Abstract][Full Text] [Related]
12. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
[TBL] [Abstract][Full Text] [Related]
13. Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1.
Mehlan J; Schüttauf F; Salamon JM; Kordes U; Friedrich RE; Mautner VF
Anticancer Res; 2019 Feb; 39(2):827-831. PubMed ID: 30711963
[TBL] [Abstract][Full Text] [Related]
14. Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening.
Levin MH; Armstrong GT; Broad JH; Zimmerman R; Bilaniuk LT; Feygin T; Li Y; Liu GT; Fisher MJ
Br J Ophthalmol; 2016 Apr; 100(4):510-4. PubMed ID: 26294105
[TBL] [Abstract][Full Text] [Related]
15. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
Pinheiro SL; Maciel J; Cavaco D; Figueiredo AA; Damásio IL; Donato S; Passos J; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):79-85. PubMed ID: 36269545
[TBL] [Abstract][Full Text] [Related]
16. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
17. Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.
Boonzaier NR; Hales PW; D'Arco F; Walters BC; Kaur R; Mankad K; Cooper J; Liasis A; Smith V; O'Hare P; Hargrave D; Clark CA
Neuroimage Clin; 2020; 28():102447. PubMed ID: 33038669
[TBL] [Abstract][Full Text] [Related]
18. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ
Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
[TBL] [Abstract][Full Text] [Related]
19. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.
Blanchard G; Lafforgue MP; Lion-François L; Kemlin I; Rodriguez D; Castelnau P; Carneiro M; Meyer P; Rivier F; Barbarot S; Chaix Y;
Eur J Paediatr Neurol; 2016 Mar; 20(2):275-281. PubMed ID: 26774135
[TBL] [Abstract][Full Text] [Related]
20. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]